Genetic Reduction of Mammalian Target of Rapamycin Ameliorates Alzheimer's Disease-Like Cognitive and Pathological Deficits by Restoring Hippocampal Gene Expression Signature
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Elevated mammalian target of rapamycin (mTOR) signaling has been found in Alzheimer's disease (AD) patients and is linked to diabetes and aging, two known risk factors for AD. However, whether hyperactive mTOR plays a role in the cognitive deficits associated with AD remains elusive. Here, we genetically reduced mTOR signaling in the brains of Tg2576 mice, a widely used animal model of AD. We found that suppression of mTOR signaling reduced amyloid-β deposits and rescued memory deficits. Mechanistically, the reduction in mTOR signaling led to an increase in autophagy induction and restored the hippocampal gene expression signature of the Tg2576 mice to wild-type levels. Our results implicate hyperactive mTOR signaling as a previous unidentified signaling pathway underlying gene-expression dysregulation and cognitive deficits in AD. Furthermore, hyperactive mTOR signaling may represent a molecular pathway by which aging contributes to the development of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 2×
“Further, overwhelming evidence shows that reducing mTOR signaling increases lifespan and health-span in a variety of organisms, including mammals (Harrison et al., 2009; Selman et al., 2009).”
BackgroundResultDefining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
mTOR signaling: At the crossroads of plasticity, memory and disease
Hoeffer, C. A., & Klann, E. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.003 · Cited by 1,128
Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span
Selman, C., Tullet, J. M. A., Wieser, D., Irvine, E., Lingard, S. J., Choudhury, A. I., Claret, M., Al-Qassab, H., Carmignac, D., Ramadani, F., et al. (2009) · Science · doi:10.1126/science.1177221 · Cited by 1,120 · cited 1×
“In contrast, some of the beneficial effects of caloric restrictions on brain function might be mediated by reduction in mTOR signaling (Speakman and Mitchell, 2011).”
BackgroundKawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053 · cited 1×
“We initially focused on A pathology, as this is the major neuropathological feature of the Tg2576 mice (Kawarabayashi et al., 2001).”
BackgroundSpilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., Richardson, A., Strong, R., & Galvan, V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009979 · Cited by 1,033 · cited 1×
“…with this hypothesis, we and others have shown that rapamycin, an mTOR inhibitor, increases lifespan in genetically heterogeneous mice and decreases AD-like pathology in two independent animal models of AD (Harrison et al., 2009; Caccamo et al., 2010; Spilman et al., 2010; Majumder et al., 2011).”
ResultReversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis
Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J. (2008) · Nature Medicine · doi:10.1038/nm1788 · Cited by 882 · cited 3×
“Toward this end, mTOR activity is necessary for memory consolidation (Tang et al., 2002; Parsons et al., 2006); however, mTOR hyperactivity is detrimental and causes cognitive deficits in animals and people (Ehninger et al., 2008; Puighermanal et al., 2009; Ehninger, 2013).”
BackgroundMolecular Interplay between Mammalian Target of Rapamycin (mTOR), Amyloid-β, and Tau
Caccamo, A., Majumder, S., Richardson, A., Strong, R., & Oddo, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.100420 · Cited by 881
Self-citationTang, S. J., Reis, G., Kang, H., Gingras, A.-C., Sonenberg, N., & Schuman, E. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012605299 · Cited by 734 · cited 2×
“Toward this end, mTOR activity is necessary for memory consolidation (Tang et al., 2002; Parsons et al., 2006); however, mTOR hyperactivity is detrimental and causes cognitive deficits in animals and people (Ehninger et al., 2008; Puighermanal et al., 2009; Ehninger, 2013).”
BackgroundKomatsu, M., Wang, Q. J., Holstein, G. R., Friedrich, V. L., Iwata, J.-I., Kominami, E., Chait, B. T., Tanaka, K., & Yue, Z. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701311104 · Cited by 614 · cited 1×
“We first measured the levels of four key autophagy related proteins (Atgs), which have been shown to be critical in autophagy induction (Mizushima et al., 1998; Komatsu et al., 2007).”
BackgroundRapalogs and mTOR inhibitors as anti-aging therapeutics
Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64099 · Cited by 531 · cited 1×
“…that reducing the activity of the mammalian target of rapamycin (mTOR) increases lifespan and health-span in several genetically different species (Lamming et al., 2013). mTOR is a ubiquitously expressed protein kinase that plays a key role in regulating protein synthesis and cell growth by…”
BackgroundGriffin, R. J., Moloney, A., Kelliher, M., Johnston, J. A., Ravid, R., Dockery, P., O'Connor, R., & O'Neill, C. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02949.x · Cited by 459 · cited 1×
“Several laboratories have reported that mTOR hyperactivity is increased in postmortem human brains compared with agematched controls (Chang et al., 2002; An et al., 2003; Peel and Bredesen, 2003; Griffin et al., 2005; Pei and Hugon, 2008; Pei et al., 2008).”
BackgroundCaccamo, A., Magrì, A., Medina, D. X., Wisely, E. V., López‐Aranda, M. F., Silva, A. J., & Oddo, S. (2013) · Aging Cell · doi:10.1111/acel.12057 · Cited by 362
Self-citationAn, W.-L., Cowburn, R. F., Li, L., Braak, H., Alafuzoff, I., Iqbal, K., Iqbal, I.-G., Winblad, B., & Pei, J.-J. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63687-5 · Cited by 312 · cited 2×
“Several laboratories have shown that mTOR signaling is upregulated in AD patients and animal models (An et al., 2003; Caccamo et al., 2010; Oddo, 2012).”
BackgroundChang, R. C. C., Wong, A. K. Y., Ng, H.-K., & Hugon, J. (2002) · NeuroReport · doi:10.1097/00001756-200212200-00011 · Cited by 289 · cited 1×
“Several laboratories have reported that mTOR hyperactivity is increased in postmortem human brains compared with agematched controls (Chang et al., 2002; An et al., 2003; Peel and Bredesen, 2003; Griffin et al., 2005; Pei and Hugon, 2008; Pei et al., 2008).”
BackgroundTOR-Mediated Cell-Cycle Activation Causes Neurodegeneration in a Drosophila Tauopathy Model
Khurana, V., Lu, Y., Steinhilb, M. L., Oldham, S., Shulman, J. M., & Feany, M. B. (2006) · Current Biology · doi:10.1016/j.cub.2005.12.042 · Cited by 266
Autophagic/lysosomal dysfunction in Alzheimer’s disease
Orr, M. E., & Oddo, S. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt217 · Cited by 199
Self-citationmTOR‐dependent signalling in Alzheimer's disease
Pei, J., & Hugon, J. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00509.x · Cited by 190 · cited 1×
“Several laboratories have reported that mTOR hyperactivity is increased in postmortem human brains compared with agematched controls (Chang et al., 2002; An et al., 2003; Peel and Bredesen, 2003; Griffin et al., 2005; Pei and Hugon, 2008; Pei et al., 2008).”
BackgroundPeel, A. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00086-x · Cited by 125
Cited by
Maternal immune activation: Implications for neuropsychiatric disorders
Estes, M. L., & McAllister, A. K. (2016) · Science · doi:10.1126/science.aag3194 · Cited by 1,206
Autophagy and Alzheimer’s Disease: From Molecular Mechanisms to Therapeutic Implications
Uddin, M. S., Stachowiak, A., Mamun, A. A., Tzvetkov, N. T., Takeda, S., Atanasov, A. G., Bergantin, L. B., Abdel-Daim, M. M., & Stankiewicz, A. M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00004 · Cited by 395
Molecular neurobiology of mTOR
Switon, K., Kotulska, K., Janusz-Kaminska, A., Zmorzynska, J., & Jaworski, J. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2016.11.017 · Cited by 387
mTOR in Brain Physiology and Pathologies
Bockaert, J., & Marin, P. (2015) · Physiological Reviews · doi:10.1152/physrev.00038.2014 · Cited by 356
Autophagy and Alzheimer’s Disease
Li, Q., Liu, Y., & Sun, M. (2017) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0386-8 · Cited by 330
Metadata
- Authors
- Caccamo, A., De Pinto, V., Messina, A., Branca, C., & Oddo, S.
- Venue
- Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2014-06-04
- Volume
- 34
- Issue
- 23
- Pages
- 7988-7998
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2071951303
- Cited by
- 182
- References
- 22
- FWCI
- 12.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.